ANRO:NYE-Alto Neuroscience, Inc. (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 13.62

Change

0.00 (0.00)%

Market Cap

USD 0.35B

Volume

0.22M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NVO Novo Nordisk A/S

-4.90 (-3.58%)

USD 585.29B
BHVN Biohaven Pharmaceutical Holdin..

-0.02 (-0.05%)

USD 3.69B
RCUS Arcus Biosciences Inc

-0.17 (-1.01%)

USD 1.64B
NUVB Nuvation Bio Inc

N/A

USD 0.70B
DNA Ginkgo Bioworks Holdings

+0.58 (+9.31%)

USD 0.35B
ADCT ADC Therapeutics SA

+0.04 (+1.30%)

USD 0.30B
CYBN Cybin Inc

N/A

USD 0.15B
ANVS Annovis Bio Inc

+0.72 (+8.98%)

USD 0.11B
MAIA MAIA Biotechnology Inc.

-0.03 (-1.01%)

USD 0.08B
ARMP Armata Pharmaceuticals Inc

+0.08 (+3.67%)

USD 0.08B

ETFs Containing ANRO

IBRN iShares Trust - iShares N.. 1,000.00 % 0.00 %

+0.01 (+0.05%)

USD 3.84M

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.35B 85% B 43% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.